Search

Introduction: Mental disorders are very serious complicated disorders. Schizophrenia is one of the most baffling mental disorders. The new series 7-(2-(benzo[d]thiazol-2- ylamino)ethoxy)-4-methyl-2H-chromen-2- synthesized in search of newer compounds for Schizophrenia. Methods: Synthesis is done by refluxing in dry pyridine with various substituted 2-amino benzothiazoles derivatives (3a-3k) and 7-(2-Chloroethoxy)-4-methyl-2H-chromen-2-one (2). The molecular docking approach was used to screen these generated derivatives. Chem Bio Draw Ultra 12 was used to draw the compounds, which were then exposed to all potential conformations of compounds interacting with receptors. The Glide 7.6, Schrodinger 2017 Maestro 11.3 was used to achieve molecular docking. The Dopamine receptor 6CM4 serotonin 5TUD PDBs were acquired from the database of Brookhaven Protein. Using the OPLS 2005 force field, the ligand-protein hydrogen-bond network was acquired, along with the overall energy reduced. A glide score was used to rate the docking poses. Results: The produced compounds have been identified with the use of analytical and spectral data. All of the produced substances were tested and analyzed for serotonin 5HT2 antagonistic and dopamine D2 activity, which can be considered as a measure of typical antipsychotic properties. Conclusion: Compounds 4b, 4c, 4e, 4g & 4i have demonstrated promising pharmacological action in preliminary studies. According to the preceding findings, compounds with electronwithdrawing substitutions, such as 4e & 4b, have a good atypical profile of antipsychotics.

The present work deals with the formulation and development of oral herbal liquid dosage and its comparative study with marketed dosage for quality evaluation parameters. We have used different Poly-herbs for the formulation of syrup because they expressed high effectiveness in a vast number of diseases. As aforementioned the therapeutic effect of herbal medicines is exerted due to the presence of different constituents and the effects are further potentiated when compatible herbals are formulated together in PHFs (Poly-herbal formulations). PHF show compatible effect with those of standard allopathic drugs. We had tested its Quality control pre and post-formulation evaluation parameters. The Quality control tests for developed herbal syrup include: Physical appearance (Color, Odor, and Taste), Clarity tests, solubility tests, pH, Density, Viscosity, Specific gravity, Refractive index, FTIR study of active constituent used in herbal syrup. This syrup is also tested for acute oral toxicity study (LD50), Antioxidant activity by using Nitric oxide free radical scavenging method, and hepato-protective activity by using paracetamol-induced hepatotoxicity in rats. From the obtained results, we concluded that formulated poly-herbal syrup passed all quality control tests and also proved its effectiveness. The formulation F2 and F3 were the best poly-herbal formulation and it was selected for further study. In hepato-protective activity, F2 formulation when compared with the standard formulation of silymarin have shown good results.

In a move to speed up the development of new medicines, the Food and Drug Administration announced in January 2006 the creation of the exploratory Investigational New Drug (IND), the so-called phase '0' clinical trials. This guidance is intended to clarify what preclinical and clinical approaches, as well as chemistry, manufacturing, and controls information, should be considered when planning exploratory studies in humans, including studies of closely related drugs or therapeutic biological products, under an IND application (21 CFR 312). Existing regulations allow a great deal of flexibility in the amount of data that needs to be submitted with an IND application, depending on the goals of the proposed investigation, the specific human testing proposed, and the expected risks. The agency believes that sponsors have not taken full advantage of that flexibility and often provide more supporting information in INDs than is required by regulations. This guidance is intended to clarify what manufacturing controls, preclinical testing, and clinical approaches can be considered when planning limited, early exploratory IND studies in humans.